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Objective: The objective of this selective EBM review is to determine whether or not clonidine 
is effective in reducing duration of treatment in infants admitted for neonatal abstinence 
syndrome (NAS). 
 
Study Design: Review of two randomized control trials and one retrospective cohort design. 
 
Data Sources: All articles were published in English in peer reviewed journals between the 
years of 2015 and 2019. Articles were obtained from peer reviewed journals and databased using 
PubMed and Cochrane Library. 
 
Outcomes: Outcomes measured were duration of treatment and duration of treatment of 
morphine, measured in days.  
 
Results: The infants treated with clonidine in Bada et al. required a statistically significantly 
shorter duration of treatment than those treated with morphine (p=0.02). Surran et al. found that 
infants who received morphine/clonidine had a statistically significant longer duration of 
treatment of morphine than the comparison group of infants treated with morphine/phenobarbital 
(p=0.001). Gullickson et al. reported a statistically significant increase in the duration of 
treatment for those who received morphine/clonidine compared to those who only received 
morphine (p=0.004). 
 
Conclusions: Based on the conflicting findings of the three trials, it is unknown if clonidine is 
efficacious in reducing the duration of treatment in infants with NAS. As NAS becomes more 
prevalent in the United States, more research needs to be done to more fully define clonidine’s 
role in treatment. 
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INTRODUCTION 
Neonatal abstinence syndrome (NAS) is the unfortunate consequence for approximately 
55% to 95% of newborns with prenatal opiate exposure.1 Though rarely a fatal condition, NAS 
can cause a wide variety of devastating signs and symptoms in a newborn, usually requiring 
hospital-stay prolonging treatments. This evidence based review evaluates two RCTs and one 
retrospective cohort comparing the efficacy of clonidine in reducing the duration of treatment in 
infants with NAS. 
The incidence of NAS has increased throughout the United States in recent years. Data 
suggest that in the United States, approximately 80 newborns are diagnosed with NAS per day.2 
The increase in the incidence of NAS has been associated with an increase in health care costs. 
NAS patients’ hospital stays cost about nine times as much as a newborn without NAS2, about 
$9,200 compared to $1,200. This is largely because patients with NAS need to stay in the 
hospital longer to receive treatment. In 2017, the HCUP reported 27,085 NAS newborn 
hospitalizations.2 That study also found that the average length of hospital stay for newborns 
with NAS was between 11 and 12 days, compared to two days for those without.2  
NAS is a multisystemic disorder that most notably causes autonomic dysregulation. The 
sudden withdrawal results in an increase in neurological excitability and neurotransmitter 
production which causes a variety of signs.3 Signs include excessive irritability and crying, 
seizures, sleep problems, hyperthermia, gastrointestinal problems,  poor feeding, and tremors.  
However, the exact cellular mechanisms of the condition remain widely unknown.3 
Non-pharmacologic treatments are implemented to support pharmacotherapy or can be 
used exclusively in mild cases of NAS. Examples include: gentle handling, swaddling, feeding 
on demand, dimmed lights, minimal noise, cuddling, maternal involvement, breastfeeding, 
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pacifiers, music therapy, and continuous monitoring.3  Morphine has historically been the 
standard first-line pharmacologic treatment for NAS. However, the longer-term safety of opiates 
in the treatment of NAS remains unknown, as such, alternatives need to be considered.4  
Clonidine is being studied for its potential role in the treatment of NAS as a non-opiate 
alternative or adjunct to the standard morphine regimen. Clonidine is an alpha-2 adrenergic 
agonist that works by inhibiting neurotransmitter production, which then decreases signs of 
NAS.4  It has been shown to be effective in reducing withdrawal symptoms in adults, which 
prompted questions about its potential as a treatment for infants as well.5 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not clonidine is 
effective in reducing duration of treatment in infants admitted for Neonatal Abstinence 
Syndrome (NAS).  
METHODS 
The articles were selected based on relevance to the clinical question and outcomes 
measured. All were published in peer-reviewed journals. The articles were obtained from 
searches of PubMed and Cochrane Library. Keywords used in searches included “clonidine” and 
“neonatal abstinence syndrome” and “morphine.” Inclusion criteria included: primary research 
studies, published in English, after October 10, 2010. The exclusion criteria included: published 
before October 6, 2010, and secondary research design. Two randomized control trials and one 
retrospective cohort design were selected for analysis. 
The population studied was infants admitted for treatment of Neonatal Abstinence 
Syndrome with prenatal opiate exposure. The three trials all implemented an interventional 
treatment of clonidine, which was compared to either morphine alone, or morphine and 
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phenobarbital.1,4,5 The outcomes included the duration of treatment and the duration of treatment 
of morphine. 1,4,5   
Table 1. Demographics & Characteristics of Included Studies  
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OUTCOMES MEASURED 
This review analyzes clonidine’s potential efficacy in reducing the duration of treatment 
in infants admitted for Neonatal Abstinence Syndrome. The outcome studied for Gullickson et 
al. and Bada et al. was the duration of treatment, measured in days.4,5 The outcome studied for 
Surran et al., where both the intervention and comparison groups included morphine, was the 
duration of treatment of morphine, measured in days.1 Surran et al. chose their primary outcome 
to be the duration of morphine treatment instead of the total duration of treatment because infants 
in the comparison groups weaned off their phenobarbital at home, which made tracking the total 
endpoint of treatment more difficult.1 
RESULTS 
Bada et al. randomized 31 infants with NAS into two control groups to receive either 
morphine 0.4mg/kg/day or clonidine 5µg/kg/day with daily dose escalation until control of 
symptoms was achieved.4 After 48 hours of symptom control, infants’ doses were weaned by 
10% every other day until treatment could be safely stopped.4 The study was double-blind, and 
all clinical and research personnel other than the clinical pharmacists were unaware of infants’ 
medication assignments.4 The infants included in the study all were <7 days old, GA ≥35 wks, 
with prenatal opioid exposure, and symptomatic with Finnegan Scores ≥8. The total inclusion 
and exclusion criteria for the study are outlined in Table 1. The Wilcoxon rank-sum test was 
used to analyze differences between the two treatment groups. There were no significant 
differences in the characteristics of infants in the two groups in regards to birth weight, 
gestational age, APGAR score, sex, postnatal age, and Finnegan score.4 The duration of 
treatment was significantly different between the two groups with the clonidine group having a 
shorter duration than morphine as shown in Table 2.4 One patient in the clonidine group was 
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excluded from the analysis due to the clinical staff’s deviation from the protocol for that patient.4 
No adverse effects such as abnormal BP or arrhythmias were found in any infants who received 
clonidine.4 
Table 2. Outcomes of Morphine and Clonidine 
 
Surran et al. conducted a randomized control trial on infants £15 days old, with prenatal 
opioid exposure, and moderate to severe NAS.1 The study was non-blinded due to different 
monitoring requirements for the two treatment groups.1 However, the randomization was 
concealed from the clinical research team, and the clinicians followed an exact protocol in 
regards to dosing and weaning procedures.1 The study compared the duration of treatment of 
morphine in infants who received clonidine/morphine versus phenobarbital/morphine.1 Complete 
inclusion and exclusion criteria for participants are detailed in Table 1. The Wilcoxon rank-sum 
test was used to analyze differences between the two treatment groups. The study reported no 
significant differences in characteristics in the two groups in regards to gestational age, birth 
weight, and 5 minute APGAR score.1 There was a significant difference in Modified Finnegan 
score and maternal oxycodone dose.1 All patients in this study were analyzed in the groups in 
which they were randomized.1 Two patients in the clonidine/morphine group were withdrawn 
from the study: one due to BZD exposure in utero and one due to a seizure condition, both 
discovered after the start of the study.1 There were no reported adverse effects from clonidine in 
any patients who received it.1 Overall, the results of the study with univariable analysis showed 
Intervention Mean Duration of Treatment 
(days) 
Standard Deviation P-value 
Clonidine 32 20.4 0.02* 
Morphine 42.7 17.8 
*= Statistically significant (P < 0.05) 
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that the phenobarbital/morphine group required significantly less duration of treatment than the 
clonidine/morphine group, as shown in Table 3.1  
Table 3. Outcomes of Clonidine/Morphine and Phenobarbital/Morphine 
 
A retrospective cohort analysis by Gullickson et al. studied symptomatic infants with 
prenatal opioid exposure treated at the IWK Health Center between 2006 and 2015 for NAS.5 
Their database identified 22 infants treated with morphine alone and 100 infants treated with 
morphine/clonidine who met the inclusion and exclusion criteria outlined in Table 1.5  Fisher’s 
exact test, t-test and Mann–Whitney U-test were used to analyze differences between the two 
treatment groups. There were no significant differences between the groups in regards to sex and 
birth weight, but there were significant differences between gestational age and 5 minute 
APGAR score.5 The study also found a significant difference between the duration of treatment 
between the two treatment groups, with infants receiving morphine alone having a shorter 
duration of treatment than those who received morphine/clonidine.5 No safety concerns or 
adverse effects were noted. 
Table 4. Outcomes of Morphine and Clonidine/Morphine 
 
 
Intervention Mean Duration of Treatment 
of Morphine (days) 
95% CI P-value 
Clonidine/Morphine 19.5 15.7, 23.2 0.001* 
Phenobarbital/Morphine 12.4 10.1, 14.7 
*= Statistically significant (P < 0.05) 





Morphine 11.3 7.6 0.004* 
Morphine/Clonidine 19.7 12.9 
*= Statistically significant (P < 0.01) 
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DISCUSSION 
 Clonidine is an alpha-2 adrenergic agonist that works by an inhibitory mechanism to 
decrease sympathetic outflow from the CNS.6 It is commonly used as adjunctive or alternative 
therapy in adults experiencing opioid withdrawal symptoms. Clonidine is also given to pediatrics 
for treatment of several different psychiatric disorders such as PTSD, conduct disorder, and 
ADHD.6 The most common adverse reactions noted include sedation, weakness, bradycardia, 
irritability, headache, fatigue, dizziness, and abdominal pain.6 Discontinuing clonidine abruptly 
can cause a rebound in withdrawal symptoms.6 Therefore, clonidine must be gradually tapered 
over several days.  
Clonidine’s use in the treatment of NAS is a fairly new concept, with only limited 
research studying it's efficacy and safety. Limitations of research availability include no three 
blinded RCTs testing clonidine as monotherapy.  The three primary research studies reviewed in 
this systematic review were not able to answer the question of clonidine’s efficacy in reducing 
the duration of treatment of NAS either, as they came to conflicting conclusions.  
There were several limitations listed in each of the studies that may have influenced the 
results and their generalizability. Bada et al. acknowledged their small sample size and failure to 
assess prenatal drug exposures by meconium assay as two limitation to the study.4 They also 
noted that some infants finished their treatment at home, which required caregivers to identify 
withdrawal symptoms and properly carry out the weaning process.4 It also required unmasking of 
the caregiver and primary care doctor.4  
  Surran et al. also mentioned limitations to their study due to lack of blinding.1 There 
was no blinding of the treatment groups due to different monitoring and dosing protocols for the 
clonidine group.1 They also noted that while the duration of the treatment of morphine was 
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shorter for those who were on phenobarbital/morphine, the total duration of treatment was much 
longer that group, which weaned phenobarbital at home for up to 8 months.1  
Gullickson et al. was limited by location, as they only conducted their analysis from 
patients in one hospital in Canada.5 They also noted that the clonidine/morphine group may have 
had a longer duration of treatment than morphine alone due consecutive weaning of morphine 
and then clonidine in the intervention group.5 Another limitation of the Gullickson et al. study 
was the small sample size in the morphine group of 22 infants, compared to 100 in the 
morphine/clonidine group.5 
Bada et al. was the only study to conduct follow-up monitoring for the participants in the 
study.4 Twelve participants in each group were evaluated in 1 year follow-up visits. There were 
no significant differences found using the Wilcoxon rank-sum test  between in the two treatment 
groups at that time in regards to language, physical growth, motor and cognitive ability.4 After 
the 1 year visit, there was no further follow-up. More thorough follow up in regarding long term 
effects of clonidine should have also been considered by Bada et al. Gullickson et al. and Surran 
et al. should have investigated potential effects of the treatment after completion as well.    
CONCLUSION 
Based on the findings of this evidence-based systematic review, it is unknown if 
clonidine is effective in reducing the duration of treatment in infants with NAS. As NAS 
becomes more prevalent in the United States, more research needs to be done to more fully 
define clonidine’s role in the treatment of NAS. Neonates are arguably the most vulnerable 
population, and those born with NAS face even more obstacles in just the first few days of life. 
More research needs to be conducted to ensure those with NAS have the best transition possible 
from the womb to the world outside. This research should focus on a multicenter trial of 
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clonidine as single-drug therapy in an infant’s treatment of NAS since that was the only 
intervention that proved a shorter duration of treatment than morphine.4 Further research should 
also include the long-term effects of clonidine in patients treated for NAS. Finally, future 
research studies should analyze the role of specific prenatal opiate agents, as well as non-opiate 
drugs, in response to different pharmacotherapies used to treat NAS. 
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